Filing Flows

Filing Flows › CytomX Therapeutics (CTMX) › Who owns the stock

Who owns CytomX Therapeutics (CTMX) stock

169 funds reported CytomX Therapeutics (CTMX) shares in their latest 13F filings, worth $833M in all. The largest holder is FMR LLC ($123M). Last quarter 105 funds added to their stakes and 75 cut them.

Largest holders of CTMX (13F)Largest holders of CTMX (13F)FMR LLC$123MKynam Capital Management, LP$81.4MBlackRock$65.8MBank of America$56.6MState Street$44.1MPerceptive Advisors LLC$39.1MVanguard Group$36.1MVanguard Capital Management LLC$32.0MPoint72 Asset Management, L.P.$29.3MWellington Management Group LLP$19.4M

Largest holders (13F)

FundSharesValueChangeQuarter
FMR LLC32,714,937$123Mincrease2026-06-30
Kynam Capital Management, LP21,703,093$81.4Mincrease2026-06-30
BlackRock17,559,822$65.8Mincrease2026-06-30
Bank of America15,082,617$56.6Mincrease2026-06-30
State Street11,747,236$44.1Mincrease2026-06-30
Perceptive Advisors LLC10,439,185$39.1Mincrease2026-06-30
Vanguard Group8,475,584$36.1Mdecrease2025-12-31
Vanguard Capital Management LLC8,525,457$32.0Mdecrease2026-06-30
Point72 Asset Management, L.P.7,811,033$29.3Mdecrease2026-06-30
Wellington Management Group LLP5,168,961$19.4Mincrease2026-06-30
VR Adviser, LLC4,982,124$18.7Mdecrease2026-06-30
Baker Bros. Advisors LP4,975,826$18.7Munchanged2026-06-30
Geode Capital Management, LLC4,678,716$17.5Mincrease2026-06-30
Elmind Capital, LP4,550,000$17.1Munchanged2026-06-30
Nextech Invest4,449,932$16.7Munchanged2026-06-30

CytomX Therapeutics' latest quarter

CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most CTMX stock?

By the latest 13F filings: FMR LLC ($123M); Kynam Capital Management, LP ($81.4M); BlackRock ($65.8M); Bank of America ($56.6M); State Street ($44.1M).

What is the short interest in CTMX?

42,790,446 shares were sold short at the 2026-10-15 settlement, 4.84% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.